Researchers have developed a targeted therapy offering new hope for patients living with a rare form of blood cancer. By focusing on specific cancer cells while sparing healthy ones, this innovation represents a significant step toward more effective and less toxic treatment options.
“People with myelofibrosis are often treated with therapies that help control symptoms, but they don’t selectively target the abnormal cells driving the disease,” said Prof Daniel Thomas, director of the South Australian Health and Medical Research Institute’s (SAHMRI) Blood Cancer programme.
“Our research shows that by focusing on what makes these cells different, it may be possible to develop treatments that are both more effective and more targeted. This is part of a major paradigm shift in the treatment of myelofibrosis and related diseases,” Thomas added.
Using the patient cells, the team found two different targets that optimally remove the culprit cells.
The study highlights the potential of precision immunology, an approach that uses the immune system to recognise and act on disease-causing cells while leaving healthy cells largely unaffected.
The findings suggest that different biological forms of the disease may benefit from different targeted strategies.
“The future of cancer treatment lies in understanding disease at a molecular and immune level and then translating that knowledge into therapies that are, potent, long-lasting and precise,” Angel Lopez, Head of Human Immunology at SA Pathology,
While the findings are promising, further research and clinical development are needed before the approach can be tested in patients.
At KKLT, we know that every breakthrough brings us closer to a future where blood cancer is no longer a life-threatening diagnosis. But progress like this is only possible through continued research, awareness, and community support.
What this means:
• More precise and personalised treatment options
• Reduced side effects compared to traditional therapies
• Renewed hope for patients and families facing rare diagnoses
Why it matters:
Many rare blood cancers still lack effective treatments. Advancements like this highlight the critical need to invest in research and expand access to innovative care.
Be part of the change
Support life-saving research. Raise awareness. Help us reach more patients in need.
Together, we can turn breakthroughs into survival stories.
